Research and Education > Cutting-Edge Research > SPORE Projects > SPORE Project 1

SPORE Project 1


Project 1 - TARGETING REDOX DEPENDENCY TO TREAT PANCREATIC CANCER
                  
David A. Tuveson, M.D., Ph.D. (CSHL) – Basic Co-Leader
                   Kenneth Ho-ming Yu, M.D. (CSHL) – Clinical Co-Leader

Project 1 will determine whether pharmacologic manipulation of redox regulation in PDAC cells provides new therapeutic strategies to circumvent chemoresistance and improve the care of patients with localized or metastatic PDAC. Pharmacologic regulation of NRF2, and thus redox signaling, will be evaluated alone and in combination with translation inhibitors, Ras effector antagonists, and standard chemotherapies. The novel organoid model system and mouse models developed in the Tuveson laboratory will be used in Aim 1 to prioritize the most effective approaches for the development and implementation of an early phase clinical trial of redox directed therapies for patients with advanced PDAC in Aim 2.

Image text